公开(公告)号：WO2005096836A1

公开(公告)日：2005-10-20

申请号：PCT/CA2005/000517

申请日：2005-04-06

Applicant: UNIVERSITY OF SASKATCHEWAN ,  CLASSEN, Henry, L. ,  QIAO, Hongyu

Inventor： CLASSEN, Henry, L. ,  QIAO, Hongyu

IPC: A23K1/16

CPC classification number: A61K31/192 ,  A23K20/111

Abstract: An animal feed composition for monogastric non-human animals is disclosed comprising supplemental sinapic acid or derivatives thereof. Sinapic acid may be supplemented at a level of from 0.0005% to 3% of the feed composition by weight. The feed composition has the beneficial effect of promoting favourable intestinal microbial ecology by reducing pathogenic microbial populations, increasing favourable microbial populations, and increasing performance and growth characteristics in livestock animals.

Abstract translation: 公开了用于单胃非人动物的动物饲料组合物，其包含补充的芥子酸或其衍生物。 辛酸可以以饲料组合物重量的0.0005％至3％的量补充。 饲料组合物通过减少病原微生物群落，增加有利的微生物群体，增加家畜的表现和生长特性，有利于促进肠道微生物生态。

公开(公告)号：WO2003099175A1

公开(公告)日：2003-12-04

申请号：PCT/CA2003/000774

申请日：2003-05-29

Applicant: UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES INC. ,  GRAHN, Bruce, Harold ,  STOREY, Eric, Shad ,  STILLING, Denise, Sharon

Inventor： GRAHN, Bruce, Harold ,  STOREY, Eric, Shad ,  STILLING, Denise, Sharon

IPC: A61F9/007

CPC classification number: A61M27/002 ,  A61F9/0017 ,  A61F9/00781 ,  A61M39/22 ,  A61M2210/0612

Abstract: This invention provides a shunt for implantation between the anterior chamber of the eye and the epithelial-lined space through the frontal sinus bone of a patient for the treatment of glaucoma. The shunt includes a tube having a length sufficient to span the distance between the anterior chamber of the eye and the epithelial-lined space of the patient, the tube having an open anterior chamber end and a closed epithelial-lined space end, and a seal device associated with the tube between the anterior chamber and epithelial-lined space ends, for sealing a hole in the frontal sinus bone, and for anchoring the tube against movement from the frontal sinus bone. The shunt also includes a fluid pressure openable valve in the tube, located at or near the epithelial-lined space sinus end, allowing for controlled flow of aqueous humor through the tube when implanted. The invention also extends to a method of treating glaucoma in a patient by surgically implanting the shunt between the anterior chamber of the eye and the frontal sinus.

Abstract translation: 本发明提供了一种用于在眼前房和通过患者的额窦骨的上皮内衬空间之间植入用于治疗青光眼的分流器。 该分流器包括具有足以跨越眼睛前房与患者上皮衬里空间之间距离的长度的管，该管具有开放的前房末端和封闭的上皮内衬空间端，以及密封 与前房和上皮衬里的空间端之间的管相关联的装置，用于密封额窦骨中的孔，并用于锚固管以防止从额窦骨移动。 分流器还包括管中的流体压力可打开的阀，位于上皮内衬的空间窦端处或附近，允许房水在植入时通过管的受控流动。 本发明还延伸到通过在眼前房和额窦之间手术植入分流器来治疗患者青光眼的方法。

公开(公告)号：WO2003089666A3

公开(公告)日：2003-10-30

申请号：PCT/CA2003/000574

申请日：2003-04-17

Applicant: UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES INC. ,  LEE, Jeremy, S. ,  WETTIG, Shawn, D. ,  KRAATZ, Heinz-Bernhard

Inventor： LEE, Jeremy, S. ,  WETTIG, Shawn, D. ,  KRAATZ, Heinz-Bernhard

IPC: G11C13/02

Abstract: In various aspects, the invention provides molecular systems for storing and retrieving information. In some embodiments, polymers capable of selectively binding metal ions, such as nucleic acids, are used to record information in the form of a particular molecular conformation. Electrochemical assay methods employing nanopores may be used to read and write information using such polymeric media. In some embodiments, information may be recorded in a nucleic acid polymer by magnetically modulating the translocation of the nucleic acid through a channel in a medium, while simultaneously modulating the electrostatic potential across the channel. In this way, the incorporation of a divalent metal ion in the nucleic acid duplex may be modulated to store information. In an alternative aspect, the invention provides analogous processes for detecting a base pair mismatch in a nucleic acid polymer.

公开(公告)号：WO2003014357A1

公开(公告)日：2003-02-20

申请号：PCT/CA2002/001051

申请日：2002-07-10

Applicant: UNIVERSITY OF SASKATCHEWAN ,  POZNIAK, Curtis, J. ,  HUCL, Pierre

Inventor： POZNIAK, Curtis, J. ,  HUCL, Pierre

IPC: C12N15/60

CPC classification number: C12N15/8274 ,  A01H5/10 ,  A01N43/50 ,  C12N9/88 ,  C12N15/8278 ,  C12Q1/6895 ,  C12Q2600/13 ,  C12Q2600/156 ,  C12Y401/03

Abstract: The present invention is directed to wheat plants having increased resistance to an imidazolinone herbicide. More particularly, the present invention includes wheat plants containing one or more IMI nucleic acids such as a Teal IMI cultivar. The nucleic acids are preferably located on or derived from different genomes. The present invention also includes seeds produced by these wheat plants and methods of controlling weeds in the vicinity of these wheat plants.

Abstract translation: 本发明涉及对咪唑啉酮除草剂具有增加的抗性的小麦植物。 更具体地，本发明包括含有一种或多种IMI核酸如小麦IMI品种的小麦植物。 核酸优选位于不同基因组上或衍生自不同基因组。 本发明还包括由这些小麦植物生产的种子以及在这些小麦植物附近控制杂草的方法。

公开(公告)号：WO2002077210A2

公开(公告)日：2002-10-03

申请号：PCT/CA2002/000413

申请日：2002-03-27

Applicant: UNIVERSITY OF SASKATCHEWAN ,  LIU, Qiang ,  TIKOO, Suresh, K. ,  WILLSON, Philip ,  BABIUK, Lorne, A.

Inventor： LIU, Qiang ,  TIKOO, Suresh, K. ,  WILLSON, Philip ,  BABIUK, Lorne, A.

IPC: C12N7/00

CPC classification number: C07K14/005 ,  A61K2039/525 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10322 ,  C12N2750/10021 ,  C12N2750/10043 ,  C12N2750/10052

Abstract: The present invention relates to methods for culturing circovirus and in particular, porcine circovirus. The present invention provides compositions and methods for culturing porcine circovirus in mammalian cells expressing mammalian adenovirus E1 function.

Abstract translation: 本发明涉及培养圆环病毒，特别是猪圆环病毒的方法。 本发明提供了在表达哺乳动物腺病毒E1功能的哺乳动物细胞中培养猪圆环病毒的组合物和方法。

公开(公告)号：WO1996040628A1

公开(公告)日：1996-12-19

申请号：PCT/CA1996000380

申请日：1996-06-07

Applicant: THE UNIVERSITY OF SASKATCHEWAN ,  DIMMOCK, Jonathan, Richard ,  PUTHUCODE, Ramanan, Narayan

Inventor： THE UNIVERSITY OF SASKATCHEWAN

IPC: C07C281/14

CPC classification number: C07C281/14

Abstract: A compound of general formula (I) useful as an anticonvulsant for disorders of the central nervous system wherein: R , R , R and R may be the same or different and each represents a hydrogen or halogen atom, or a C1-9alkyl, C3-9cycloalkyl, cyano, C1-9alkoxy or C6-10aryloxy group; R represents a hydrogen atom or a C1-9alkyl, C3-9cycloalkyl or C6-10aryl group; and X is oxygen or sulfur; or a pharmaceutically-acceptable salt thereof. The compound may be administered orally for treating convulsions in humans or animals.

Abstract translation: 用作中枢神经系统障碍的抗惊厥药的通式（I）化合物，其中：R 1，R 2，R 3和R 4可以相同或不同，并且各自表示 氢或卤原子，或C1-9烷基，C3-9环烷基，氰基，C1-9烷氧基或C6-10芳氧基; R 5表示氢原子或C 1-8烷基，C 3-9环烷基或C 6-10芳基; X为氧或硫; 或其药学上可接受的盐。 该化合物可以口服给药以治疗人或动物的抽搐。

公开(公告)号：WO1994024296A2

公开(公告)日：1994-10-27

申请号：PCT/CA1994000201

申请日：1994-04-19

Applicant: UNIVERSITY OF SASKATCHEWAN

Inventor： UNIVERSITY OF SASKATCHEWAN ,  ZAMB, Timothy ,  LIANG, Xiaoping ,  RABUIK, Lorne, A.

IPC: C12N15/86

CPC classification number: C12N15/86 ,  A61K39/00 ,  A61K39/12 ,  A61K39/265 ,  A61K2039/5254 ,  A61K2039/552 ,  C07K14/005 ,  C12N15/85 ,  C12N2710/16722 ,  C12N2710/16734 ,  C12N2710/16743 ,  C12N2800/60 ,  C12N2830/00 ,  C12N2830/60

Abstract: Vaccines compositions comprising a pharmaceutically acceptable vehicle and a mutant bovine herpesvirus 1 (BHV-1) wherein (i) at least one non-essential gene of wild-type BHV-1 is deleted and optionally replaced with a gene selected from the group consisting of a foreign gene, a gene encoding a BHV-1 immunogen and a mutant analog of a gene encoding a BHV-1 immunogen; and wherein (ii) the replacement gene is optionally under the control of a promoter; and further wherein (iii) at least one essential gene of wild-type BHV-1 is optionally mutated are provided. Vaccines compositions comprising a pharmaceutically acceptable vehicle and a bovine herpesvirus 1 (BHV-1) wherein (i) at least one non-essential gene is deleted or (ii) an essential gene is mutated are also provided. In addition, related vectors, DNA constructs, a diagnostic assay and methods for treating and preventing BHV-1 infection and other bacterial and viral pathogens of cattle are provided.

Abstract translation: 包含药学上可接受的载体和突变体牛疱疹病毒1（BHV-1）的疫苗组合物，其中（i）野生型BHV-1的至少一种非必需基因被缺失，并且任选地被选自以下的基因替换： 外源基因，编码BHV-1免疫原的基因和编码BHV-1免疫原的基因的突变体类似物; 并且其中（ii）所述置换基因任选地在启动子的控制下; 并且其中（iii）提供野生型BHV-1的至少一种必需基因被任选突变。 还提供了包含药学上可接受的载体和牛疱疹病毒1（BHV-1）的疫苗组合物，其中（i）至少一个非必需基因被缺失或（ii）必需基因被突变。 此外，还提供了相关载体，DNA构建体，诊断测定法和用于治疗和预防牛的BHV-1感染和其他细菌和病毒病原体的方法。

公开(公告)号：WO1994006758A1

公开(公告)日：1994-03-31

申请号：PCT/CA1993000386

申请日：1993-09-21

Applicant: UNIVERSITY OF SASKATCHEWAN

Inventor： UNIVERSITY OF SASKATCHEWAN ,  DIMMOCK, Jonathan, R.

IPC: C07C281/10

CPC classification number: C07C281/14 ,  A61K31/175 ,  C07C281/10

Abstract: A number of aryl semicarbazones were prepared as candidate anticonvulsants. When administered orally to rats, significant activity was noted in the maximal electroshock (MES) screen and since neurotoxicity was either absent or reduced (as compared to intraperitoneal injection in mice), high protection indices were found in the majority of the compounds. The semicarbazones displayed little or no activity in the subcutaneous pentylenetetrazol screen. These observations support the theory that one large hydrophobic group (in this case the aryl ring) are requirements for protection in the MES screen. In general, the semicarbazones had rapid onsets of action and the most common mechanism of action was interaction with chloride channels. Empirical and semi-empirical conformational calculations indicated that certain molecular fragments and hydrophobicity of these molecules affect bioactivity.

Abstract translation: 制备了许多芳基缩氨基脲作为候选抗惊厥药。 当大鼠口服给药时，在最大电击（MES）屏幕中观察到显着的活性，并且由于神经毒性不存在或减少（与小鼠腹膜内注射相比），在大多数化合物中发现高保护指数。 氨基脲在皮下戊四氮屏幕中显示很少或没有活性。 这些观察结果支持一个大的疏水基团（在这种情况下是芳环）是MES屏幕中的保护要求的理论。 一般来说，缩氨基脲具有快速的作用机制，最常见的作用机制是与氯离子通道相互作用。 经验和半经验构象计算表明某些分子片段和这些分子的疏水性影响生物活性。

公开(公告)号：WO1993023023A1

公开(公告)日：1993-11-25

申请号：PCT/CA1993000198

申请日：1993-05-14

Applicant: UNIVERSITY OF SASKATCHEWAN ,  YU, Peter, H. ,  ZUO, Dong-Mei

Inventor： UNIVERSITY OF SASKATCHEWAN

IPC: A61K31/135

CPC classification number: A61K31/15 ,  A61K31/135 ,  A61K31/175

Abstract: A method for preventing endothelium damage in mammals, particularly for the treatment of cardiovascular disorders associated to diabetes and uraemia. The invention also relates to a method for alleviating pain associated with gout and arthritis in mammals. The method comprises administering to a mammal an effective amount of an SSAO inhibitor to block the formation of formaldehyde in the endothelium or cartilage tissues for the purpose of treating cardiovascular disorders associated to diabetes and uraemia or for alleviating pain associated with gout and arthritis.

Abstract translation: 一种用于预防哺乳动物内皮损伤的方法，特别是用于治疗与糖尿病和尿血症有关的心血管疾病。 本发明还涉及一种减轻与哺乳动物痛风和关节炎有关的疼痛的方法。 该方法包括向哺乳动物施用有效量的SSAO抑制剂，以阻止内皮或软骨组织中的甲醛形成，用于治疗与糖尿病和尿失禁相关的心血管疾病或减轻与痛风和关节炎相关的疼痛。

公开(公告)号：WO1993008290A1

公开(公告)日：1993-04-29

申请号：PCT/CA1992000449

申请日：1992-10-15

Applicant: UNIVERSITY OF SASKATCHEWAN

Inventor： UNIVERSITY OF SASKATCHEWAN ,  POTTER, Andrew, A. ,  REDMOND, Mark, J. ,  HUGHES, Huw, P., A.

IPC: C12N15/62

CPC classification number: C07K14/005 ,  A61K39/00 ,  A61K39/0006 ,  A61K47/62 ,  A61K47/646 ,  A61K47/6829 ,  A61K47/6833 ,  A61K2039/6037 ,  C07K5/1019 ,  C07K5/1021 ,  C07K5/1024 ,  C07K7/23 ,  C07K14/285 ,  C07K14/655 ,  C07K16/26 ,  C07K2319/00 ,  C12N2720/12322

Abstract: New immunological carrier systems, DNA encoding the same, and the use of these systems, are disclosed. The carrier systems include chimeric proteins which comprise a leukotoxin polypeptide fused to a selected antigen. The leukotoxin functions to increase the immunogenicity of the antigen fused thereto.

Abstract translation: 公开了新的免疫载体系统，编码相同的DNA以及这些系统的使用。 载体体系包括嵌合蛋白，其包含与选定抗原融合的白细胞毒素多肽。 白细胞毒素用于增加融合在其上的抗原的免疫原性。